Skip to content. | Skip to navigation


Personal tools
 

Dr. Christian Steidl, MD

Publications

 

Published Refereed Papers | Books and Chapters | Presentations as a Guest Speaker | Published Abstracts

         2011

  1. Steidl C and Gascoyne RD. The molecular pathogenesis of primary mediastinal large B cell lymphoma. Blood. 2011;118(10):2659-69.

  2. Eberle FC, Salaverria I, Steidl C, Summers Jr TA, Pittaluga S, Ben Neriah S, Rodriguez-Canales J, Xi L, Ylaya K, Liewehr D, Dunleavy K, Wilson WH, Hewitt SM, Raffeld M, Gascoyne RD, Siebert R, Jaffe ES. Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. Modern Pathology. 2011 Aug 5 [Epub ahead of print]

  3. Steidl C, Connors JM and Gascoyne RD. The Molecular Pathogenesis of Hodgkin Lymphoma: Increasing Evidence of the Importance of the Microenvironment. Journal of Clinical Oncology 2011;10;29(14):1812-26.

  4. Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, Scott DW, Steidl C, Wiseman SM, Gascoyne RD, Gilks B, Huntsman DG. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. Journal of Pathology 2011;224(3):328-33.

  5. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Ben Neriah S, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA and Gascoyne RD. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011;471(7338):377-81.

  6. Steidl C, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica 2011;96(2):186-9.

  7. Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C, Lübbert M, Stauder R, Krieger O, Garcia-Manero G, Kantarjian H, Germing U, Haase D and Estey E. Coalesced multicentric analysis of 2351 patients with MDS indicates an underestimation of poor risk cytogenetics in the International Prognostic Scoring System of myelodysplastic syndromes. Journal of Clinical Oncology. 2011;29(15):1963-70.

  8. Mallo M, Cervera J, Schanz J, Such E, García-Manero G, Luño E, Steidl C, Espinet B, Vallespí T, Germing U, Blum S, Ohyashiki K, Grau J, Pfeilstöcker M, Hernández J, Noesslinger T, Giagounidis A, Aul C, Calasanz J, Martín L, Valent P, Collado R, Haferlach C, Fonatsch C, Lübbert M, Stauder R, Hildebrandt B, Krieger O, Pedro C, Arenillas L, Sanz MA, Valencia A, Florensa L, Sanz GF, Haase D, Solé F. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia.2011;70(22):9166-74.

    2010

  9. Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, Xiao W, Powell J, Maloney D, Thomas CJ, Moller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM. Cooperative Epigenetic Modulation by Cancer Amplicon Genes. Cancer Cell 2010;18(6):590–605.

  10. Cheung KJ, Johnson N, Affleck J, Severson T, Steidl C, Ben-Neriah S, Schein J, Morin RD, Moore R, Shah SP, Qian H, Paul J, Telenius A, Relander T, Lam WL, Savage KJ, Connors J, Brown C, Marra MA, Gascoyne RD, Horsman D. Acquired TNFRSF14 mutations in follicular lymphoma are associated with inferior prognosis. Cancer Res 2010;70(22):9166-74.

  11. Steidl C, Telenius A, Shah SP, Farinha P, Barclay L, Boyle M, Connors JM, Horsman DE, Gascoyne RD. Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome. Blood. 2010;116(3):418-27

  12. Steidl C, Tang L, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast M, Rosenwald A, Muller-Hermelink HK, Rimsza L, Campo E, Delabie J, Braziel R, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD. Tumor-associated macrophages and survival in classical Hodgkin lymphoma. N Engl J Med. 2010;362(10):875-85.

  13. Murphy D, Parker J, Zhou M, Fadlelmola FM, Steidl C, Karsan A, Gascoyne RD, Chen H, Banerjee D. Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B). Mol Cancer. 2010;9:14.
  14. Shustik J, Han G, Farinha P, Johnson NA, Ben Neriah S, Connors JM, Sehn LH, Horsman DE, Gascoyne RD, Steidl C. Outcome correlations of BCL6 rearrangement in diffuse large B cell lymphoma treated with CHOP or R-CHOP. Haematologica. 2010;95(1):96-101.

    2009
  15. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature. 2009;461(7265):809-13.
  16. Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer MJ, Siebert R, Kuruvilla J, Klasa R, Connors JM, Gascoyne RD, Horsman DE. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009;114(11):2273-9.  
  17. Cheung KJ, Shah SP, Steidl C, Johnson N, Relander T, Telenius A, Lai B, Murphy KP, Lam W, Al-Tourah AJ, Connors JM, Ng RT, Gascoyne RD, Horsman DE. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood. 2009;113(1):137-48.

    2007

  18.  Steidl C, Schanz J, Pfeilstoecker M, Noesslinger T, Hildebrandt B, Kuendgen A, Lübbert M, Kunzmann R, Giagounidis A, Aul C, Trümper L, Krieger O, Stauder R, Müller T, Wimazal F, Valent P, Fonatsch C, Germing U, Haase D. Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes. Clinical Leukemia. 2007; 1(6):353-356.

  19. Haase D, Germing U, Schanz J, Pfeilstoecker M, Noesslinger T, Hildebrandt B, Kuendgen A, Luebbert M, Kunzmann R, Giagounidis A, Aul C, Truemper L, Krieger O, Stauder R, Mueller TH, Wimazal F, Valent P, Fonatsch C, Steidl C. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patietns. Blood. 2007;110(13):4385-95.

  20. Steidl U*, Steidl C*, Ebralidze A, Chapuy B, Hye-Jung H, Will B, Rosenbauer F, Becker B, Wagner K, Koschmieder S, Kobayashi S, Schulz T, O’Brien KB, Verhaak RGW, Delwel R, Haase D, Truemper L, Krauter J, Kohwi-Shigematsu T, Griesinger F, Tenen DG. A single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. J Clin Invest. 2007;117(9):2611-20 *both authors contributed equally to this work

    2006  

  21. Steidl U, Rosenbauer F, Verhaak RG, Gu X, Ebralidze A, Otu HH, Klippel S, Steidl C, Bruns I, Costa DB, Wagner K, Aivado M, Kobbe G, Valk PJ, Passegue E, Libermann TA, Delwel R, Tenen DG. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet. 2006;38(11):1269-77.

  22. Kuendgen A., Schmid M., Schlenk R., Knipp S., Hildebrandt B., Steidl C., Germing U., Haas R., Döhner H., Gattermann N. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer. 2006;106(1):112-9 

Books and Chapters

 

Published Refereed Papers | Books and Chapters | Presentations as a Guest Speaker | Published Abstracts

          2011

  1. Cytogenetics of MDS” in The Myelodysplastic Syndromes. (Editor: Varkonyi, Judit). Springer Berlin Heidelberg, Germany, 2011.

  2. “What will we learn from Genomics and Proteomics in Hodgkin Lymphoma?” (Editors: Andreas Engert and Sandra J. Horning). Springer Berlin Heidelberg, 2010.

  3. “Cytogenetic and molecular diagnostics” in MDS and acute myeloid leukemia: a biological and therapeutic continuum. (Editor: Prof. Dr. Michael Luebbert). UNI-MED Verlag AG, Bremen Germany, 2007

 

Presentations as a Guest Speaker

 

Published Refereed Papers | Books and Chapters | Presentations as a Guest Speaker | Published Abstracts         

          2011

  1. A molecular approach to Hodgkin Lymphoma: Understanding treatment failure. 1st International Symposium on Childhood Adolescent and Young Adult Hodgkin Lymphoma (ISCAYAHL), Invited lecture, Arlington, VA, 2011.

  2. Fusion gene discovery in lymphoid cancers using next generation sequencing, Invited lecture, Cincinnati Children’s Hospital Medical Center, Cincinnati, 2011

    2010

  3. Genome-wide copy number analysis of microdissected HRS cells in classical Hodgkin lymphoma, 8th International Symposium on Hodgkin lymphoma, Cologne, Germany, 2010

  4. Molecular characterization of Hodgkin lymphoma: Genome-wide approaches for biomarker discovery, 2010 Annual Cancer Conference of the BC Cancer Agency, Vancouver, 2010

  5. Genomics approaches for biomarker discovery in Hodgkin lymphoma, Invited lecture, Albert-Einstein College of Medicine, New York, 2010

  6. Molecular characterization of Hodgkin lymphoma: Genome-wide approaches for biomarker discovery, Invited lecture, Weill Cornell Medical College, New York, 2010

    2009

  7. Gene Expression Profiling of Microdissected Hodgkin Reed Sternberg Cells: Molecular Subtypes and Treatment Outcome Correlations, 51st American Society of Hematology (ASH) meeting, New Orleans, 2009

    2008

  8. Genetic Alterations Detected by High-Resolution Array Comparative Genomic Hybridization in Microdissected HRS Cells Correlate with Treatment Outcome in Classical Hodgkin Lymphoma, 50th American Society of Hematology (ASH) meeting, San Francisco, 2008

  9. Genome- Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma, 50th American Society of Hematology (ASH) meeting, San Francisco, 2008

    2007

  10. Gene expression profiling in Hodgkin Lymphoma: The HRS cells or the microenvironment? 7th International Symposium on Hodgkin Lymphoma, Cologne 2007

  11. Immune Microenvironment in Hodgkin Lymphoma, The BC Cancer Immunotherapy Workshop, Vancouver, Canada, 2007

    2004

  12. Karyotype evolution in myelodysplastic syndromes, 17th Working Symposium of Tumour Cytogenetics, Hohwacht, Germany, 2004

  13. Karyotype evolution and complex chromosome rearrangements in AML and MDS, 5th Annual Symposium of the German Competence Network, Acute and chronic Leukemias, Heidelberg, Germany, 2004

    2002

  14. Quality management in tumour cytogenetics, 13th Annual Symposium of the German Society of Human Genetics, Leipzig, Germany, 2002

    2000

  15. Chromosomal aberrations in bladder cancer and adjacent urothelium, 31st Meeting of the German Society of Pathology, Bonn, Germany, 2000

 

Published Abstracts

 

Published Refereed Papers | Books and Chapters | Presentations as a Guest Speaker | Published Abstracts        

         2010 

  1. C. Ganster, F. Braulke, K. Shirneshan, F. Solé, M. Mallo, J. Cervera, E. Luno, B. Hildebrandt, C. Steidl, C. Fonatsch, M. Pfeilstöcker, T. Nösslinger, P. Valent, A. Giagounidis, C. Aul, M. Lübbert, R. Stauder, O. Krieger, M.M. Le Beau, J.M. Bennett, P.L. Greenberg, U. Germing, D. Haase, and Julie Schanz. Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality? Blood, Nov 2010;116:4008. (abstr.)

  2. J. Schanz, H. Tüchler, F. Sole, M. Mallo, B. Hildebrandt, C. Steidl, C. Fonatsch, M. Pfeilstöcker, T. Nösslinger, P. Valent, A. Giagounidis, M. Lübbert, R. Stauder, O. Krieger, M.M. Le Beau, J.M. Bennett, P.L. Greenberg, U. Germing, and Detlef Haase. Prognostic Impact of Monosomy 7 as a Single Anomaly In Primary MDS – Reclassification From Poor to Intermediate Prognosis. Blood, Nov 2010;116:1861. (abstr.)

  3. N.A. Johnson, J.M. Connors, S. Ben-Neriah, S. Rogic, K.J. Savage, C. Steidl, D.E. Horsman, G.W. Slack, L. Sehn, W.C. Chan, J. Iqbal, P.N. Meyer, G. Lenz, G.W. Wright, L.M. Rimsza, C. Valentino, P. Brunhoeber, T. Grogan, R.M. Braziel, J. Cook, R.R. Tubbs, D.D. Weisenburger, E. Campo, A. Rosenwald, G. Ott, J. Delabie, E. Jaffe, L.M. Staudt, and R.D. Gascoyne. Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. Blood, Nov 2010; 116: 2005. (abstr.)

    2009

  4. A.J. Mungall, A. Chu, R. Chiu, R. Corbett, M.A. Field, S.D. Jackman, K.L. Mungall, K. Wong, M. Boyle, R. Carlsen, S.Y. Chan, R.J.N. Coope, C.A. Hirst, M. Hirst, N. Johnson, M. Krzywinski, D. Lee, J. BingXue Lin, R. Moore, T. Severson, J.T. Simpson, C. Steidl, T. Zeng, Y. Zhao, I. Birol, R.A. Holt, S.J. Jones, R.D. Gascoyne, D.E. Horsman, J.M. Connors, J.E. Schein, and M.A. Marra. Base-Pair Resolution of Somatic and Germline- Derived Genome Rearrangement Breakpoints in Follicular Lymphoma. Blood, Nov 2009;114:39 (abstr.).

  5. K.-J. Cheung, N. Johnson, J. Affleck, T. Severson, C. Steidl, S. Ben-Neriah, J.    Schein, R. Morin, R. Moore, S.P. Shah, H. Qian, J. Paul, A. Telenius, B. Lai, T. Relander, W.L. Lam, K.J. Savage, J.M. Connors, C. Brown, M. Marra, R.D. Gascoyne, and D.E. Horsman. TNFRSF14 Is Mutated in a Subset of Follicular Lymphoma and Correlated with Inferior Prognosis. Blood, Nov 2009; 114: 1919 (abstr.).
  6. P. Farinha, C. Steidl, L.M. Rimsza, K.J. Savage, J.M. Connors, and R.D. Gascoyne. HLA-DR  Protein  Expression  Correlates  with  Non-Neoplastic  T-Cell  Infiltration  and Predicts Survival in Patients with Primary Mediastinal Large B Cell Lymphoma (PMBCL) Treated with CHOP Chemotherapy. Blood, Nov 2009; 114: 133 (abstr.).
  7. C. Steidl, T. Lee, P. Farinha, A. Telenius, M. Boyle, S.P. Shah, L. Barclay, J.M. Connors, and R.D. Gascoyne. Gene Expression Profiling of Microdissected Hodgkin Reed Sternberg Cells: Molecular Subtypes and Treatment Outcome Correlations. Blood, Nov 2009; 114: 268 (abstr.).
  8. J. Schanz, H. Tuechler, F. Solé, M. Mallo, B. Hildebrandt, M.L. Slovak, K. Ohyashiki, C. Steidl, C. Fonatsch, M. Pfeilstoecker, T. Noesslinger, P. Valent, A. Giagounidis, M. Luebbert, R. Stauder, O. Krieger, M.M. Le Beau, J.M. Bennett, P.L. Greenberg, U. Germing, and D. Haase. Cytogenetic Risk Features in MDS-Update and Present State. Blood, Nov 2009; 114: 2772 (abstr.).


    2008
  9. J. Shustik, C. Steidl, L. Sehn, and R.D. Gascoyne. Prognostic Significance of BCL6 Translocation in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP. Blood, Nov 2008; 112: 3782 (abstr.).
  10. N.A. Johnson, K.J. Savage, S. Ben-Neriah, C. Steidl, R. Klasa, J.M. Connors, R.D. Gascoyne,  and  D.E.  Horsman.  Lymphomas  with  Concurrent  T(14;18)  and  8q24 Translocations Are Under- Reported and Clinical Outcome Depends on the MYC Partner. Blood, Nov 2008; 112: 804 (abstr.).
  11. C. Steidl, Adele Telenius, Sohrab P. Shah, K-John Cheung, Lorena Barclay, Joseph M. Connors, Douglas E. Horsman, and Randy D. Gascoyne. Genetic Alterations Detected by Correlate with Treatment Outcome in Classical Hodgkin Lymphoma. Blood, Nov 2008;112: 522 (abstr.).
  12. C. Steidl, T. Lee, S. P. Shah, G. Han, T. Nayar, A. Delaney, S. Jones, W.C. Chan, A. Rosenwald, L.M. Rimsza, E.Campo, E.S. Jaffe, L.M. Staudt, G. Lenz, J.M. Connors, and R.D. Gascoyne. Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma. Blood, Nov 2008; 112: 520 (abstr.).
  13. M. del Mar Mallo, J. Cervera, J. Schanz, B. Espinet, E. Such, E. Luño, C. Steidl, M.L. Martín, U. Germing, J. Grau, M. Pfeilstoecker, J.M. Hernández, T. Noesslinger, M. a José Calasanz, P. Valent, R. Collado, C. Fonatsch, E. Bureo, M. Lübbert, R. Ríos, R. Stauder, E. Arranz, B. Hildebrandt, M.L. Slovak, J. Cigudosa, V. Eclache, O. Krieger, C. Pedro, M. Salido, L. Arenillas, G. Sanz, M.A. Sanz, A. Valencia, L. Florensa, D. Haase, and F. Solé Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome. Blood, Nov 2008; 112: 1649 (abstr.).
  14. J.  Schanz,  M.L.  Slovak,  K.  Ohyashiki,  F.  Solé,  M.  del  Mar  Mallo,  C.  Steidl,  M. Pfeilstoecker,   T.   Noesslinger,   B.   Hildebrandt,   M.   Luebbert,   M.K.   Andersen,   A. Giagounidis, P. Valent, C. Fonatsch, U. Germing, and D. Haase. New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics. Blood, Nov 2008; 112: 2688 (abstr.).


    2007
  15. J. Schanz, E.H. Estey, C. Steidl, U. Germing, B. Hildebrandt, G. Garcia-Manero, H.M. Kantarjian, and D. Haase. Multivariate Analysis Suggests That the Prognostic Impact of Poor Cytogenetics Is Potentially Underestimated in the IPSS. Blood, Nov 2007; 110: 248 (abstr.).
  16. D. Haase, E.H. Estey, C. Steidl, U. Germing, G. Garcia-Manero, H.M. Kantarjian, and J. Schanz. Multivariate Evaluation of the Prognostic and Therapeutic Relevance of Cytogenetics in a Merged European-American Cohort of 3860 Patients with MDS. Blood, Nov 2007; 110: 247 (abstr.).
  17. C. Steidl, J. Schanz, M.M. Le Beau, J.M. Bennett, U. Germing, P.L. Greenberg, and D. Haase. Coalescence of the German-Austrian and IMRAW Cytogenetic MDS Databases: Modification of Patient Risk Groups. Blood, Nov 2007; 110: 2468 (abstr.).
  18. K.-J. Cheung, A. Telenius, B. Lai, N. Johnson, T. Relander, C. Steidl, A. Baross, H. Qian, J. Schein, M. Marra, J.M. Connors, R.D. Gascoyne, and D.E. Horsman. High Frequency of 1p36.32 Deletion or Loss of Heterozygosity in Follicular Lymphoma (FL). Blood, Nov 2007; 110: 183 (abstr.).
  19. U. Steidl, C. Steidl, A. Ebralidze, B. Chapuy, H.-J. Han, B. Will, F. Rosenbauer, A. Becker, K., S. Koschmieder, S. Kobayashi, D.B. Costa, T. Schulz, K.B. O’Brien, R.G.W. Verhaak, R. Delwel, D. Haase, L. Trumper, J. Krauter, T. Kohwi-Shigematsu, F. Griesinger, and D.G. Tenen. A Distal Single Nucleotide Polymorphism Disrupts Development-Dependent Long-Range Transcriptional Regulation of the PU.1 Gene through the Chromatin-Remodeling Protein SATB1 in Acute Myeloid Leukemia. Blood, Nov 2007; 110: 3175 (abstr.)
  20. C. Steidl, A. Telenius, J. Connors, D. Horsman and R.D. Gascoyne. Genetic imbalances in microdissected HRS cells: patterns of alterations and differences between treatment responders and failures. Haematologica 2007 (abstr.)
  21. R.D. Gascoyne, T. Nayar, T. Lee, N. Johnson, J.M. Connors and C. Steidl.  Predicting outcome in   classical   Hodgkin   Lymphoma:   the   role   of   the   microenvironment. Haematologica 2007 (abstr.)
  22. C. Steidl, T. Nayar, T. Lee, A. Telenius, N. Johnson, D. Horsman, J. Connors, R.D. Gascoyne. Gene expression profiling of microdissected HRS cells in classical Hodgkin Lymphoma. Haematologica 2007 (abstr.)

    2006
  23. D. Haase, U. Germing, J. Schanz, M. Pfeilstoecker, B. Hildebrandt, M. Luebbert, A. Giagounidis, C. Aul, L. Truemper, T. Mueller, P. Valent, N. Gattermann, C. Fonatsch, O. Krieger, R. Stauder, and C. Steidl.  Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS. Blood, Nov 2006; 108: 252. (abstr.)
  24. D. Haase, U. Germing, J. Schanz, M. Pfeilstoecker, T. Noesslinger, B. Hildebrandt, A. Kuendgen, M. Luebbert, A. Giagounidis, C. Aul, L. Truemper, T. Mueller, P. Valent, C. Fonatsch, and C. Steidl. New and Comprehensive Cytogenetic Prognostication and Categorization in MDS. Blood, Nov 2006; 108: 248. (abstr.)

 

Back to Christian Steidl

Back to Main Page